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Abstract: Cyclin-dependent kinases (CDKs) and their inhibitors (CDKIs) play pivotal roles in the
regulation of the cell cycle. As a result of these functions, it may be extrapolated that they are essential
for appropriate embryonic development. The twenty known mouse CDKs and eight CDKIs have
been studied to varying degrees in the developing mouse, but only a handful of CDKs and a single
CDKI have been shown to be absolutely required for murine embryonic development. What has
become apparent, as more studies have shone light on these family members, is that in addition to
their primary functional role in regulating the cell cycle, many of these genes are also controlling
specific cell fates by directing differentiation in various tissues. Here we review the extensive mouse
models that have been generated to study the functions of CDKs and CDKIs, and discuss their varying
roles in murine embryonic development, with a particular focus on the brain, pancreas and fertility.
Keywords: cyclin-dependent kinase; CDK inhibitors; mouse; development; knock-out models
1. Introduction
Cyclin-dependent kinases (CDKs) are proteins that, by definition, require the binding of partner
cyclin proteins in order to phosphorylate a series of target proteins. These complexes are required for
appropriate progression of the cell cycle and, as such, are essential for development. CDK inhibitors
(CDKIs) are a class of proteins that preferentially bind to and inhibit the activity of CDK/cyclin
complexes and are thus involved in stopping or delaying the progression of the cell cycle. The roles
and functional redundancies of CDKs and CDKIs in regulating the cell cycle have been extensively
reviewed previously [1–3]. The structures of these proteins, including potential sites for interactions
with inhibitors, have also been extensively studied and reviewed [4–8].
Twenty CDKs have been described in the mammalian genome, derived from a single ancestral gene
in yeast, and many of these have been shown to be expressed during embryonic development [9,10].
Likewise, there are two major families of CDKIs: the CIP/KIP family, encoded by the Cdkn1 gene family
comprising p21CIP1, p27KIP1 and p57KIP2; and the INK4 family, encoded by the Cdkn2 gene family
comprising p16INK4a, p15INK4b, p18INK4c and p19INK4d. Many CDKIs have been shown to play key
roles in embryonic development [11–13]. In addition to their shared ability to modulate the cell cycle,
several of these CDKs and CDKIs have been shown to direct differentiation of a number of different cell
types with a particular convergence in the brain, pancreas and gonadal ridges, which will be discussed
in greater detail later on.
For many of these proteins, their functions have been studied primarily through knock-out (KO)
mouse models and cell lines. These are mice or cells with one or both alleles of the gene in question
constitutively deleted from the genome with any phenotypic abnormalities ostensibly due to the
absence of the specified protein. In the case of CDKs and CDKIs, family members often display
redundant functions, and as a result, many of the expected phenotypes that might be caused by the
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absence of a family member can be compensated for by other members, or even evolutionarily distant
homologues, despite low sequence conservation [14,15]. To elucidate the extent of this compensation
within gene families, researchers have frequently generated double (dKO) and triple (tKO) KO mouse
lines of selected family members. Additionally, conditional KO (cKO) models can be used where the
gene deletion is triggered through Cre-recombinase activity, allowing the deletion to be tissue-specific or
induced at a desired time point. In this way, cKO animals can provide additional information about
a protein’s function by focussing on a particular developmental area and are particularly useful for
bypassing a constitutive KO’s embryonic lethality.
This review aims to summarise the known functions of CDKs and CDKIs in murine development,
with a particular focus on development of the brain, pancreas, sperm and oocytes, principally using
information gained from mouse models. The phenotypes of mouse CDK and CDKI KOs have been
previously reviewed and an updated profile is provided here with a focus on development (Tables 1
and 2) [3,16–20]. The primary organs affected by each CDK and CDKI, as analysed through mouse
KOs, are shown schematically in Figure 1, with KOs of Cdk1, Cdk4, Cdk6, Cdk11, Cdk13, Cdkn1b, Cdkn1c
and Cdkn2c affecting overall embryonic development.
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Figure 1. Schematic of principal areas of CDK and CDKI involvement during murine development, as
determined by KO and cKO mouse models. The ears, brain, pituitary gland, eyes, spine, lungs, heart,
liver, pancreas, kidneys, spleen, intestine and testes/ovaries are colour-coded based on the presence of
an altered phenotype upon KO of a CDK or CDKI, depicted here in an E17.5 mouse embryo. The area
of each colour is not reflective of the magnitude of the effect on the mouse phenotype. KOs of Cdk1,
Cdk4, Cdk6, Cdk11, Cdk13, Cdkn1b, Cdkn1c and Cdkn2c affect overall embryonic development.
Int. J. Mol. Sci. 2020, 21, 5343 4 of 23
Table 1. Phenotypes of CDK (cyclin-dependent kinase) KO (knock-out) and cKO (conditional KO) in mice.
CDK Developmental Region KO Phenotypes References
Cdk1
Whole Body Mutant line with truncated protein–homozygous early embryonic lethal [21]
Whole Body KO–lethal at the 1-cell stage due to inability to complete cell division [22]
Testes cKO in spermatocytes–cells arrest at prometaphase resulting in male infertility [23]
Ovaries cKO in oocytes–females infertile due to failure to resume meiosis. Rescued withmicroinjection of Cdk1 [24]
Brain cKO in Nex (postmitotic neurons of cortex and hippocampus)–normal brain development [25]
Liver cKO in liver–failure to complete cell division but normal phenotype due to compensatorycell growth [22]
Cdk2
Whole Body/
Testes/Ovaries
KO–develop normally but both sexes sterile. Spermatocytes and oocytes arrest at prophase
I, oocytes slightly later than spermatocytes [26]
Whole Body/
Testes/Ovaries KO–normal development but both sexes infertile [27]
Ovaries cKO in oocytes–develop normally [24]
Cdk3 Whole Body Null point mutation–normal development. Possible functional redundancy [28]
Cdk4
Whole Body/
Testes/Ovaries/
Endocrine System/
Pancreas
KO–reduced mutant numbers in heterozygous cross, suggesting some embryonic lethality.
Decreased body size. Defective spermatogenesis reducing fertility. Females infertile due to
deficit in hypothalamic-pituitary axis. Mice are insulin-deficient diabetic due to affected
β-cells.
[29]
Whole Body/
Pancreas/
Testes/Ovaries
KO–mice are undersized and develop diabetes as above. Males show testicular atrophy
due to defective proliferation of gonocytes and hypoplastic seminiferous tubules. Female
infertility due to perturbed corpus luteum formation
[30]
Whole Body/
Endocrine System
KO–decreased body size with small pituitaries, with particularly reduced lactotrophs
resulting in female infertility [31]
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Table 1. Cont.
CDK Developmental Region KO Phenotypes References
Cdk5
Brain KO–>60% die in utero; altered brain development [32]
Brain KO–reduced phosphorylation of histone H1 by Cdk16 in the brain [33]
Brain cKO in CaMKII (forebrain)–seizures, tremors, growth retardation, layer disruption andneurogenerative changes that progressed with age [34]
Brain cKO in CaMKII–behavioural changes, increased susceptibility to cocaine [35]
Brain cKO in CNP cells–hypomyelination and impaired learning and memory [36]
Brain cKO in CNP cells–loss of myelin repair [37]
Brain cKO in EMX1–impaired differentiation of oligodendrocytes [38]
Brain cKO in EMX1–defective layer structure in cerebral cortex [39]
Brain cKO in mid and hindbrain– small cerebellum and altered dendritic development [40]
Cdk6 Whole Body/ Immune System KO–undersized females. Underdeveloped thymus and spleen. Mild anaemia due todefects in haematopoiesis [41]
Cdk7
Cdk8
Whole Body/
Intestine KO–normal growth, but increased size and growth rate of intestinal tumours [42]
Pancreas cKO in β-cells–improved glucose tolerance due to increased insulin secretion. Increasedcell death following stress conditions [43]
Cdk9 Whole Body KO–complete embryonic lethality from day E9.5 *
Cdk10
Cdk11 Whole Body KO–early embryonic lethal between days E3.5 and E4. Cells exhibit growth defects andmitotic arrest, resulting in blastocyte apoptosis [44]
Cdk12
Cdk13
Whole Body/
Lung/Liver/
Kidney/Heart
Null mutant–developmental delay, growth retardation, underdeveloped lungs, liver and
kidneys. Embryo lethal due to heart defect [45]
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Table 1. Cont.
CDK Developmental Region KO Phenotypes References
Cdk14
Cdk15
Cdk16/PCTAIRE1 Testes/Ovaries cKO–failure of spermatogenesis. Female fertility normal [46]
Cdk17/PCTAIRE2 Whole Body/Brain Exon deletion–partial embryonic lethality. Increased vertical activity *
Cdk18/PCTAIRE3 Brain Exon deletion–abnormal behavioural responses to light *
Cdk19
Cdk20
Blank rows indicate a lack of experimental data for the indicated gene, to the best of our knowledge. * Mouse model is available from the International Mouse Phenotyping Consortium,
but a referenced embryonic study could not be found.
Table 2. Phenotypes of CDKI (cyclin-dependent kinase inhibitors) KO and cKO in mice.
CDKI Protein Developmental Region KO Phenotypes References
Cdkn1a p21CIP1
Whole Body KO–no spontaneous tumorigenesis [47]
Brain KO–increased neural migration and differentiation in response to brain injury [48]
Intestine KO–increased susceptibility to intestinal tumours [49]
Immune System KO–no altered susceptibility to retrovirally induced lymphatic tumours [50]
Immune System cKO in T cells–hyposensitive to programmed cell death in response toradiation-induced DNA damage [51]
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Table 2. Cont.
CDKI Protein Developmental Region KO Phenotypes References
Cdkn1b p27KIP1
Whole Body/Endocrine
System/Ovaries
KO–oversized with larger internal organs, especially the pituitary, and female sterility
due to impairment of the formation of corpora lutea [52]
Whole Body/
Endocrine System/Ovaries
KO–oversized due to increased cell number and proliferation. Females infertile due to
impaired luteal cell differentiation reflecting a disturbance in the
hypothalamic–pituitary–ovarian axis
[53]
Whole Body/
Immune System/
Endocrine System/Eyes/
Ovaries
KO–oversized, especially in thymus, pituitary and adrenal glands and gonadal organs.
Disturbed organization of retinas. Female sterility due to impaired development of
ovarian follicles
[54]
Endocrine System/Intestine/
Lung
KO–increased susceptibility to pituitary and intestinal tumours, lesions of the female
reproductive tract and lung adenomas following exposure to carcinogens [55]
Heart/Ovaries KO–protective delay of ageing and apoptosis of heart due to ovariectomy byupregulating antioxidant enzymes [56]
Testes KO–decreased testosterone production, despite increased proliferation oftestosterone-producing cells [57]
Brain KO–altered neuron migration and differentiation [58]
Brain KO–increased neural progenitor cell proliferation under basal and injury conditions [59]
Brain KO–increased cell proliferation of lower layer neurons [60]
Immune System KO–increased susceptibility to retrovirally induced lymphatic tumours. Increasedspleen proliferation [50]
Immune System KO–developed spontaneous T cell lymphomas [61]
Eyes KO–increased cell proliferation and poor repair response after photoreceptor damage [62]
Int. J. Mol. Sci. 2020, 21, 5343 8 of 23
Table 2. Cont.
CDKI Protein Developmental Region KO Phenotypes References
Cdkn1c p57KIP2
Whole Body/
Intestine/
Kidney/Spine/
Endocrine System/Eyes
KO–locational defects in small intestine and muscle. Neonatal lethality due to
breathing difficulty from cleft palate. Undersized kidneys, delayed bone development
and enlarged adrenal gland. Increased lens cell proliferation and apoptosis
[63]
Whole Body/
Intestine
KO–neonatal lethality, cleft palate, gastrointestinal abnormalities and short limbs.
Increased apoptosis [64]
Whole Body/
Spine/Testes/
Ovaries
KO–cleft palate and bone malformations. Most died within 24 hours of birth due to
difficulties breathing. Surviving mice showed severe growth retardation. Both sexes
were sexually immature
[65]
Whole Body/
Brain
KO–oversized embryo and macrocephaly, with increased cell proliferation,
particularly of neuronal precursors and lower layer neurons. Decreased cell cycle
length and increased cell cycle exit at days E14.5 and E16.5
[60]
Kidney KO–normal kidney differentiation and development [66]
Whole Body/
Spine cKO maternally–skeletal deformities, reduced body size and perinatal lethality [67]
Whole Body cKO maternally–perinatal lethality, overgrowth during early gestation and weaning,but constrained growth in late gestation [68]
Brain cKO paternally–decreased brain size and reduced number of neural progenitor cellsduring development [69]
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Table 2. Cont.
CDKI Protein Developmental Region KO Phenotypes References
Cdkn2a p16INK4a
Whole Body/
Testes/Ovaries
KO–no morphological or behavioural malformations. No significant increase in
spontaneous tumours. Fertile [70]
Brain KO–increased susceptibility to CNS tumours and hydrocephaly followingcarcinogenic exposure [71]
Immune System KO–normal development, but with thymic hyperplasia [72]
Heart KO–increased cardiomyocyte proliferation and cardiac repair [73]
Kidney KO–increased kidney cell proliferation and decreased apoptosis in response toischemia-reperfusion injury [74]
Lung KO–reduced inflammation in response to cigarette smoke, but no change toproinflammatory cytokine response [75]
Lung cKO in lung epithelia–reduction in inflammation response to cigarette smoke andsuppression of proinflammatory cytokines, but no protective effect [75]
Lung cKO in pleura–no development of malignant mesotheliomas [76]
Spine cKO in intervertebral disc–no change in senescence, reduced apoptosis and alteredmatrix homeostasis [77]
Cdkn2b p15INK4b
Whole Body/
Testes/Ovaries/
Immune System
KO–viable and fertile with no morphological or behavioural abnormalities at birth.
After two months of age, mice had atypical haematopoiesis and increased
lymphocytes in the spleen
[78]
Cdkn2c p18INK4c
Whole Body/
Endocrine System/
Immune System
KO–gigantism and organomegaly, particularly of the pituitary, spleen and thymus,
due to altered cell cycle control. Altered cell cycle entry of resting B cells [79]
Whole Body/
Testes/Ovaries/
Immune System/
Endocrine System
KO–viable and fertile with no morphological or behavioural abnormalities at birth.
From six months of age mice developed splenomegaly, enlarged lymph nodes and
increased incidence of pituitary tumours
[78]
Endocrine System/Immune
System
KO–spontaneous pituitary and lymphatic tumours. Also observed in heterozygous
mice, implying haploinsufficiency [80]
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Table 2. Cont.
CDKI Protein Developmental Region KO Phenotypes References
Cdkn2d p19INK4d
Whole Body/
Testes
KO–normal growth with no obvious malformations. Decreased, but not total loss of,
male fertility due to testicular atrophy and increased apoptosis of germ cells [81]
Immune System KO–increase in mean ploidy level in bone marrow [82]
Ears KO–aberrant cell cycle entry and subsequent apoptosis in sensory hairs leading tohearing loss [83]
Cdkn3 Brain Exon deletion–decreased grip strength *
* Mouse model is available from the International Mouse Phenotyping Consortium, but a referenced study could not be found.
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2. Absolute Requirement of Cdk1
Cdk1 is essential for successful completion of the cell cycle [18,21], preventing the creation
of constitutive Cdk1−/− cell lines or mouse models. Attempts to create Cdk1−/− offspring result in
immediate failure following fertilisation, due to the inability to successfully complete cell division.
This requirement cannot be compensated for by other members of the CDK family [84] and is even
observed in a mutant line with cassette insertion resulting in heterozygous cells expressing only 50%
of wild-type levels of Cdk1, which also results in early embryonic lethality [22]. It is therefore perhaps
surprising that such a requirement for successful completion of the cell cycle is not observed in any of
the other CDK family members.
Cdk1 is also indispensable for cell cycle completion during gamete development [85]. It is essential
for the formation of sperm, as Cdk1 cKO spermatocytes result in cell arrest at prometaphase and thus
male infertility [23]. Additionally, Cdk1 cKO oocytes lead to female infertility as the oocytes are unable
to resume meiosis, with a microinjection of Cdk1 rescuing the phenotype, thus confirming the necessity
of Cdk1 in mouse female fertility [24]. Cdk1 maintains phosphorylation of protein phosphatase 1 and
lamin A/C for meiosis resumption in the oocytes [24], and is necessary as one of the factors required
to phosphorylate eIF4E-BP1, a protein involved in facilitating spindle formation and stability during
meiosis in oocytes [86]. Cdk1 phosphorylation is believed to be particularly required for resumption of
meiosis in oocytes, with a natural increase in Cdk1 levels in later life resulting in speeding up meiosis
I, thus potentially leading to errors such as aneuploidy in later-life pregnancies [87]. This can be
ameliorated by inducing excess cyclin B1, as exploitation of preferential destruction of unbound B1
results in sustained Cdk1 levels, prolonging the cell cycle, and thus reducing aneuploidy errors [88].
Other members of the CDK family, in particular Cdk2, are also required for fertility, as discussed below.
3. Embryo
We would predict that loss of expression of any of the CDK family members would result in
impaired embryonic growth, due to disruption in the normal pathways of the cell cycle. Indeed,
this trend is largely followed, with Cdk4 and Cdk6 null animals displaying reduced embryonic
growth [27,29,31,41,89], and Cdk11−/− embryos failing to progress beyond day E4.5 [44]. While Cdk4
is not absolutely required for embryonic viability, Cdk4−/− animals are born at a reduced frequency
from heterozygous matings, suggesting partial embryonic lethality [29]. Cdk3, however, appears to be
functionally redundant, as a null point mutation was not found to affect embryonic development [28].
While single KOs of Cdk2, Cdk4 and Cdk6 are viable, this may be due to functional redundancy as
tKO mice without Cdk2, Cdk4 and Cdk6 begin dying at day E13.5 of gestation, and have malformed
livers and hearts exhibiting thinner ventricular walls than wild-type mice [21]. It is thought that loss of
Cdk4 in particular is key for the embryonic lethality of the tKO, with Cdk2 and Cdk6 dKO mice being
viable but exhibiting a combination of the phenotypes seen in Cdk2 and Cdk6 single KOs, such as
reduced body size and haematopoietic defects [41].
A functional relationship between Cdk2 and Cdk4 remains unclear, with one study showing that
a Cdk2 and Cdk4 dKO also results in embryonic death at around day E15, due to heart defects [90].
In contrast, another study found that Cdk2 and Cdk4 dKO mice complete embryonic development and
are born, slightly underweight, but die shortly after birth, potentially also due to heart failure [91].
Cdk4 KO mice with a Cdk2 ERT cKO however, show similar developmental phenotypes to Cdk4 KO
mice [91].
Cdk4 and Cdk6 dKO mice have altered haematopoiesis resulting in severe anaemia, with embryos
being undersized and beginning to die from day E14.5, with pups that survive to birth dying soon
afterwards [41]. A partial dKO where one allele of Cdk4 is expressed but Cdk6 is knocked-out results
in viable offspring, while expression of one allele of Cdk6 and complete Cdk4 KO results in partial
embryonic lethality, again suggesting that Cdk4 has the more important role in embryonic viability [41].
In contrast to Cdk2, Cdk4 and Cdk6, which all display some degree of functional redundancy,
deletions of Cdk5, Cdk11 and Cdk13 display variable levels of embryonic lethality in isolation [32,44,45].
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Cdk5 expression is largely restricted to the brain, with constitutive and neuron-specific deletion of the
gene resulting in overlapping phenotypes and perinatal lethality (~60%) [32]. Cdk11−/− blastocysts are
terminated around day E3.5 due to a massive failure in mitosis [44], while Cdk13−/− embryos fail by
day E16.5 [45]. For the remaining CDKs, a number remain untargeted, restricting our knowledge of
their potential impact on embryonic growth parameters.
The data generated from CDK mouse models largely corresponds with the presumed function of
promoting embryonic growth. Conversely, we would expect that expression of CDKIs will consequently
restrict embryonic growth, due to negative regulation of the cell cycle. It is therefore surprising that
although control of the cell cycle at G1/S phase was impaired in the absence of Cdkn1a (p21CIP1) [47],
most likely through a general reduction in inhibition of CDK activity, the mouse model did not present
with altered embryonic growth parameters. This finding is in stark contrast to the other members
of the CIP/KIP family of CDKIs. Indeed, Cdkn1b−/− mice, which lack p27KIP1, are oversized due to
increased cell proliferation, and exhibit proportionally larger internal organs [52–54]. This phenotype
was not accompanied by reduced embryonic survival. However, the loss of control of the cell cycle did
present with postnatal tumour formation [54]. It has been noted that many of the functions of Cdkn1b
and Cdkn1c are functionally redundant, with a dKO line displaying greatly enhanced phenotypes of
the single KOs [92]. tKO mice lacking all Cdkn1 family members develop normally until mid-gestation,
dying around day E13.5, marginally earlier than Cdkn1b/Cdkn1c dKO mice at day E15.5, with both
Cdkn1a/Cdkn1b and Cdkn1a/Cdkn1c dKO mice surviving past this point [93]. Knock-in of p27KIP1 to
replace p57KIP2 results in viable and healthy mice, with only a few developmental defects, suggesting
p27KIP1 and p57KIP2 have overlapping but not identical developmental roles [94]. Both p27KIP1 and
p57KIP2 appear to be expressed frequently in postmitotic cells, with the role of p57KIP2 restricted to
organogenesis, as expression is not maintained into adulthood, while p27KIP1 is expressed both during
development and in adult mice [95].
Individually, Cdkn1c must be viewed in a slightly different light to its family members, as this gene
undergoes genomic imprinting. The paternally inherited allele of this gene is epigenetically silenced
throughout the mouse’s life-course, with functionally monoallelic expression from the maternally
inherited allele [96]. To the best of our knowledge, none of the other CDKs or CDKIs have been
shown to undergo this process. As a result of this, a heterozygous deletion of just the paternal
allele (silenced) results in wild type expression levels of the gene, while a deletion of the maternal
allele (active) presents as functionally homozygous-null. Independent deletions of this gene have
shown near total late perinatal or very early neonatal lethality [64,65,67,97]. The reasons for this
lethality remain unclear, as although mice present with a cleft palate, preventing feeding and causing
breathing difficulties [63–65], this would not explain the large degree of perinatal lethality that is
observed. Likely the cleft palate represents one of a number of defects that combine to cause lethality,
alongside abdominal wall and heart defects. Due to the role of Cdkn1c in blocking the cell cycle,
it would be predicted that null animals would be overgrown. However, no such phenotype is observed
at birth [63–65,68,98]. Instead, researchers have found a complex picture, where early embryonic
overgrowth is lost in the late stages of a pregnancy, due to a restriction in growth potential in part
attributable to the size of mouse litters [68]. Partly mirroring these results, increased dosage of Cdkn1c
through the use of bacterial artificial chromosomes (BAC) has found an exquisitely dosage-sensitive
embryonic growth restriction phenotype [99].
While a plethora of work has examined the roles of the CIP/KIP family in embryonic growth
and development, the function of the INK4 family in the embryo remains comparatively untested,
with studies predominantly focussed on postnatal consequences and tumour formation following
deletion of a family member. Loss of Cdkn2c (p18INK4c) results in giantism and organomegaly,
with the organomegaly phenotype increased upon dKO with Cdkn1b (p27KIP1) [79]. Both Cdkn2b
(p15INK4a)/Cdkn2c (p18INK4c) and Cdkn2c (p18INK4c)/Cdkn2d (p19INK4d) dKO mice are viable with no
morphological or behavioural abnormalities at birth [78,100]. While we cannot assume that this is the
extent of the roles for the INK4 family in the regulation of embryonic growth, it must be remembered
Int. J. Mol. Sci. 2020, 21, 5343 13 of 23
that this family of proteins is specific in its activity towards Cdk4/6 complexes, while the CIP/KIP
family displays a more general inhibition of CDK family activity [101], potentially differentiating the
families with regards to embryonic requirements.
4. Brain Development and Function
Functional roles for CDKs in brain development have so far been restricted to just a handful.
While it is essential for embryonic development and assumedly in brain development, Cdk1 does
not appear to have a postmitotic role in neurons, with a cKO in such cells resulting in normal
development [25]. Further testing of a Cdk1 role in different regions of the brain remains unfeasible
outside of postmitotic cells.
Cdk5 has been shown to be essential in mouse brain development, with cKOs indicating a variety
of functions in various regions of the brain, overcoming the embryonic lethality observed in constitutive
KOs. A constitutive KO of Cdk5 results in altered brain development, with more than 60% of developing
embryos dying in utero [32]. cKOs of Cdk5 do not result in the same embryonic lethality, but still cause
behavioural issues [34–36]. The dosage and activity of Cdk5 is tightly regulated in the brain [102]; in
particular, p35 and p39 are both essential for Cdk5 activity and may be the principal activators of
Cdk5 [103]. Cdk5 is involved in dendritic spine formation, is important in Purkinje cell migration and
dendritic growth, and is required for formation of ventral striation; loss of Cdk5 causes GABAergic
neuronal death in the developing mouse foetus, as shown in p35 cKO and p39 KO mice [104–106].
Cdk5 phosphorylation of the neural protein Synapsin III is needed to regulate neurite outgrowth
and axonal elongation [107]. Cdk5 phosphorylation is also required for the membrane targeting of,
and promotion of proteasome-dependent degradation of Cx43, a protein involved in neuron migration
and embryonic brain development, which is associated with adult anxiety-related behaviour [108].
Loss of Cdk5 specifically in CNP cells affects myelination and results in impaired learning and
memory [36,37]. CaMKII Cdk5 cKO, which results in deletion in the mouse forebrain, causes many
behavioural abnormalities, seizures, and, intriguingly, increased susceptibility to cocaine [34,35],
while absence of Cdk5 in the mid and hind-brain or in Emx1-expressing cells, which are involved in
corticogenesis, results only in morphological defects with no reported behavioural changes [38–40].
It is interesting to note that despite none of the CDKIs having a specific affinity for Cdk5, it is the only
CDK to have overlapping expression patterns in the brain with CDKI family members.
All three members of the CIP/KIP family have described roles in neural development and
regulation. Interestingly, while the role of Cdkn1a appears to exclusively revolve around its ability to
regulate cell cycle progression [48], Cdkn1b and Cdkn1c both perform this role, and in addition to this,
are responsible for directing differentiation of a number of neural cell types [58–60]. Cdkn1b and Cdkn1c
are expressed transiently in the brain during development [95], withCdkn1c being expressed in the brain
at day E11.5-E13.5 [109]. Cdkn1c has been shown to suppress growth with a constitutive KO resulting in
macrocephaly due to an increased number of cortical precursors entering the cell cycle, which combines
with a shortened cell cycle length and leads to an increase in cortical surface, thickness and cell
numbers [60]. However, this impact has recently been shown to only occur non-cell-autonomously,
with neuronal cell-specific KOs identifying a cell-autonomous role of Cdkn1c that promotes growth
and cell survival [110]. Mosaic analysis with double markers technology was used to show that
this cell-autonomous role is dependent on the existence of the locus, regardless of parental origin or
transcription [110]. This role is further solidified by the observation that overexpression of Cdkn1c in
embryos is associated with a reduction in the number of cortical progenitor cells leading to a decrease
in upper layer neurons in the developing brain [111]. Finally, a recent study has hinted at a possible
role for the paternal allele of Cdkn1c in neocortical development, despite this gene being paternally
imprinted and therefore not transcribed [69].
An oligodendrocyte disorder resulting in loss of white brain matter links increased progenitor
cell proliferation and increased differentiation with increased Cdk2 and decreased p21CIP1 and p27KIP1
activity [112]. Additionally, impairment of potassium channels in the brain related to seizure disorders
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was reversed by decreased Cdk2 or increased p27KIP1 activity [113]. In wild-type embryos, p27KIP1
expression is found to occur along a gradient in developing neural tubes, with the highest expression
in postmitotic cells of the neuroepithelium, with the deletion of a component of the nuclear pore
complex showing a correlation between altered p27KIP1 expression patterns and abnormalities in cell
proliferation during development [114].
The INK4 CDKI family does not appear to have an important role in the developing mouse brain,
with no known studies showing a requirement for any of the Cdkn2 genes. Indeed, even a dKO of both
Cdkn2c and Cdkn2d appears to result in no neurological defects [100].
5. Pancreas
Both CDKs and CDKIs appear to have a role in insulin regulation, as changes in their expression
affect pancreatic development, with a particular functional convergence in islets. Cdk4 in particular
is vital to pancreatic function as a Cdk4−/− model results in mice with greatly impaired insulin
secretion [29,30]. In contrast, a Cdk8 cKO specific to β-cells increases insulin secretion and thus
improves glucose tolerance [43]. However, these cells have lost their ability to deal with stress, leading
to increased apoptosis under oxidative stress [43]. Phosphorylation of Ngn3 by CDKs, including Cdk1
and Cdk2, controls differentiation of endocrine cells in the embryonic pancreas and is required to
maintain adult β-cell function [115]. The importance of CDKs in controlling the pancreatic tissue cell
cycle is attracting pharmaceutical interest, with CDK inhibitors being shown as potentially viable novel
approaches to treat pancreatic adenocarcinomas [116].
The specific roles of CDKIs in pancreatic development are less clear. A dKO of Cdkn2c and Cdkn2d
causes hyperplasia of pancreatic β-cells [100], but no other role for the INK4 family in the pancreas
has yet been identified. KOs of members of the CIP/KIP family do not appear to greatly affect the
developing pancreas, but their expression is still evident. For instance, upregulation of Cdkn1a in the
pancreas is associated with a decrease in islet cell proliferation [117]. While p57KIP2 expression has been
observed in the pancreas, most notably at day E13.5 and then rapidly declining [109], p27KIP1 does not
appear to be expressed [95]. Rat p57KIP2 is highly homologous to mouse p57KIP2, while both differ
from human p57KIP2 [118]. Similar to mice, rat p57KIP2 expression is tightly controlled in the pancreas,
decreasing at birth and increasing again two weeks after birth, but is not evident in β-cells [118].
A complex picture has emerged for Cdkn1c whereby the gene indirectly regulates islet mass and β-cell
populations [119]. Overexpression models have found newborn mice to have significantly altered
blood glucose profiles, which are then retained through to adulthood [120]. Some of the exact nature
of this role remains unclear, in part due to the difficulty of dissecting the functions of Cdkn1c from
those of surrounding genes in the Kcnq1 imprinting cluster, with further studies needed to elucidate
these specific roles.
6. Fertility
Many CDK KO mouse models result in reduced fertility or even complete infertility, highlighting
essential roles for CDKs in mouse fertility. Cdk2, Cdk4, Cdk16 and Cdk18 have all been found to be
expressed in developing ovaries [121]. Cdk2 is isolated to premeiotic spermatocytes in the testes, while
Cdk16 andCdk18 are expressed in postmeiotic spermatids, suggesting diverse roles in male fertility [121].
In particular, Cdk2 is dispensable for growth but not fertility [122]. A Cdk2 KO causes both male and
female infertility, due to both spermatocytes and oocytes arresting at prophase I [26,27,85]. However,
an oocyte-specific Cdk2 cKO resulted in normal oocyte development, with the authors concluding
that Cdk1 was the only family member required for resumption of meiosis [24]. Cdk2 is also required
for differentiation of spermatocytes, with a loss-of-function allele resulting in increased apoptosis of
gonocyte precursors following depressed differentiation into spermatogonial stem cells [123]. A Cdk2
and Cdk6 dKO also results in infertility in both sexes, while a Cdk4 and Cdk6 dKO displays the same
infertility seen in a Cdk4 single KO, with total female infertility and partial male infertility [29–31],
signifying that Cdk6 does not have a dominant phenotype in mouse fertility [41]. The impaired
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spermatogenesis in Cdk4 KOs appears to be due to defective proliferation of gonocytes and hypoplastic
seminiferous tubules resulting in testicular atrophy [30]. A lack of Cdk4 causes female sterility
through suppressing development of the pituitary, resulting in reduced lactotrophs and a deficit in the
hypothalamic–pituitary axis, leading to perturbed corpus luteum formation [29–31]. Cdk16 interacts
with, and is phosphorylated by, cyclin Y-like1 to regulate spermatogenesis [89]. A Cdk16 cKO resulted
in structurally malformed and consequently hypomotile spermatozoa, leading to reduced male fertility,
placing Cdk16 function in the terminal stages of spermatogenesis [46]. Cdk16 does not appear to be
required for female fertility [46]. A more in-depth review of the role of CDKs in spermatogenesis has
been compiled by Palmer et al. [124].
A lack of Cdkn1b (p27KIP1) results in female sterility due to impairment of ovarian follicle
development and corpora lutea formation, believed to be related to the oversized pituitary and
thus alteration of the hypothalamic–pituitary–ovarian axis which is seen in these KO mice [52–54].
Despite having overly large testes, male fertility was not affected in Cdkn1b KO mice [54]. Loss of
Cdkn1c (p57KIP2) has been shown to result in sexual immaturity in both sexes [65]. Decreased Cdkn1a
and Cdkn1c expression in the testes is associated with mitotic arrest in the male germ cells [125]. Cdkn1c
expression is observable in rat testes at day E17, declines at day E19.5 to day E21.5, but is again evident
in spermatogonia from the second week after birth and in adult spermatids [118]. In mice, while Cdkn1b
expression has been observed in the ovaries and testes, Cdkn1c does not appear to be expressed [95].
Contrastingly, loss of Cdkn2a (p16INK4a), Cdkn2b (p16INK4b) or Cdkn2c (p18INK4c) does not appear
to affect fertility [70,78]. Additionally, mice without both Cdkn1b and Cdkn1c remain fertile [78]. Loss of
Cdkn2d (p19INK4d), however, decreases but does not abolish male fertility, due to testicular atrophy and
increased apoptosis of male germ cells [81]. Similarly, a dKO of both Cdkn2c and Cdkn2d produces fertile
females but sterile males [100]. These dKO males exhibit small testes with delayed progression through
meiosis leading to increased germ cell apoptosis and decreased sperm cell count with malformed
existing spermatozoa, suggesting both p18INK4c and p19INK4d are required to regulate differentiation
of mature sperm [100]. Alternative splicing of Cdkn2c leads to two distinct mRNAs, the shorter of
which is found in various differentiated cell types such as muscle, lung and liver, while the longer
mRNA is isolated to the testes in undifferentiated, mitotically active cells, suggesting that the two
protein isotypes have separate roles, particularly for differentiation [126]. p15INK4a, p16INK4b, p21CIP1
and p27KIP1 are all expressed in the ovary, but p16INK4b is expressed more highly than the other CDKIs
and seems to decrease during oocyte growth [127].
7. In Vitro Studies
Cdk8 andCdk19, as involved in the CDK–Mediator complex, are vital for regulating gene expression
following differentiation of embryonic stem cells into neuronal precursors [128]. Cdk8 in particular
is needed to bind to distal enhancers to promote gene activation upon differentiation [128]. In the
absence of Jdp2, p21CIP1 is required to bind to antioxidant response elements of the Slc7a11 promoter
in order to provide redox control and block random oxygen species mediated apoptosis in granule cell
progenitors, an essential component for normal development of the cerebellum [129].
Cdk16 is required for dendrite development and is regulated by Cdk5 phosphorylation [130].
Cdk16 binds to p35 and is phosphorylated by Cdk5 to enhance its own kinase activity [33]. Additionally,
phosphorylation of Cdk16 by BRSK2 reduces glucose-stimulated insulin secretion in mouseβ-cells [131].
8. Discussion and Future Perspectives
While a great deal of data has been generated on the roles of both CDKs and CDKIs in murine
embryonic development, as has been presented in this review, there remains a number of as yet
entirely untested gene family members. Much of the focus of research into these families will remain
in cancer biology, given the oncogenic (CDKs) and tumour suppressing (CDKIs) nature of the groups,
respectively. There is a wealth of data being generated on the use of CDK inhibitor compounds (CDKis)
and their efficacy for tumour treatment [4,132]. While developmental biology and tumour therapy
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seem like divergent focuses, much of the data that has been generated in embryonic development can
serve as a therapeutic guide. Thanks to multiple knockout lines and environmental studies, researchers
have uncovered shared and redundant functions of both CDKs and CDKIs. This data will be invaluable
in future determinations of appropriate CDKi therapies, based on the expression profiles of the CDK
and CDKI families in tumours.
Further study of Cdk1 will remain challenging due to its critical role in cell cycle progression.
However, researchers have demonstrated that this absolute requirement can be bypassed in certain
scenarios using conditional deletions, which have also been utilized to dissect the multiple roles of
Cdk5 in brain development. There remains the opportunity to target Cdk11 and Cdk13 in a similar
manner, so as to bypass the total embryonic lethality seen in the respective constitutive knockout
mouse lines and enable cell type specific functional role analyses. Beyond these, a number of the CDKs
are awaiting their functional roles to be examined, as has been highlighted in Table 1.
The CDKIs present with a similar picture, where some family members have been studied
extensively through both constitutive and conditional deletions, while others remain to be tested.
Perhaps surprisingly, only Cdkn1c has been used to explore the impact of overexpression of a
CDKI [99,120]. These lines have shown an exquisite dosage sensitivity of the gene on both embryonic
growth and tissue differentiation. Given the known shared functional roles of the CIP/KIP family [92–95],
Cdkn1a and Cdkn1b appear to be ideal candidates for a similar targeting strategy and further exploration
of the shared and unique roles of these family members. Recently, researchers have begun applying
a novel approach to the study of these genes, through the generation of bioluminescent reporter
lines. Cdkn2a, Cdkn1b and Cdkn1c have all been independently targeted with a luciferase-reporter
to monitor endogenous gene expression in vivo [133–135]. While these lines were initially largely
developed to enable in vivo tumour formation, progressive technological development has allowed
sensitive high-resolution reporting of embryonic Cdkn1c expression in utero. This approach uncovered
a previously unseen sensitivity of the epigenetic markers that regulate this gene’s expression to
gestational dietary modification that resulted in lifelong misexpression of the gene. As a read-out
for gene expression, these models offer unparalleled insights, due to the ability to image individual
animals throughout their life-course, and therefore generate a complete picture of expression. It is
easy to envisage this approach being applied to any of the CDKs or CDKIs to explore as yet unknown
functions and provide a complementary addition to the catalogue of presently assembled mouse
models, which will continue to expand and develop our knowledge of these gene families.
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